Baird Medical Investment Holdings BDMD

Baird Medical Investment Holdings Ltd traces its history to June 2012 when Baide Suzhou Medical Co Ltd was formed in the PRC to distribute general medical devices in Guangdong. In May 2017 Baide Suzhou acquired a 51 percent stake in Nanjing Changcheng Medical Equipment Co Ltd and began developing microwave ablation medical devices. In March 2019 Baide Suzhou acquired the remaining 49 percent interest making Nanjing Changcheng a wholly owned subsidiary. The company is an exempted entity incorporated in the Cayman Islands with limited liability on June 16 2023 to effect the Business Combination. Its principal executive office is located at Room 202 2F Baide Building Building 11 No 15 Rongtong Street Yuexiu District Guangzhou Peoples Republic of China. Baird Medical Investment Holdings Ltd describes itself as a specialized healthcare innovator dedicated exclusively to thyroid related diseases. The company aims to transform traditional thyroid treatment through intelligent non invasive solutions. It seeks to build an ecosystem that spans early screening and diagnosis to robotic assisted ablation and posttreatment care. Core strengths lie in the successful development and commercialization of the thyroid microwave ablation system and an active R&D pipeline featuring AI integrated robotic systems. The firm combines hardware innovation software intelligence and a comprehensive system mindset to compete in a highly specialized market. According to the Frost & Sullivan Report Baird Medical Investment Holdings Ltd ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales volume and sales revenue of microwave ablation needles in 2022. In the same year it was the third largest microwave ablation medical device provider in the PRC by sales revenue.

The company generates revenue primarily from the sale of its proprietary microwave ablation medical devices which consist of needles and therapeutic apparatus. In 2023 microwave ablation medical devices accounted for 98 point four percent of total revenue while other medical devices contributed one point six percent. In 2024 and 2025 microwave ablation medical devices represented one hundred percent of total revenue with no contribution from other medical devices. Sales of microwave ablation needles are driven by their single use nature and the company reports having sold approximately one hundred thousand needles to date. Sales of microwave ablation therapeutic apparatus exceed one thousand three hundred units as of the date of the annual report. The company also distributes and sells other medical devices such as catheters ventilators operation tables medical gloves syringes and large medical machines though this segment is minimal. Revenue from other medical devices accounted for one point six percent of total sales in 2023 and was nil in 2024 and 2025. Hospitals in China are the ultimate customers for all products. The company reaches hospitals through three channels direct sales sales through deliverers and sales through third party distributors. Direct sales involve the company marketing products submitting tender documents and receiving payment directly from hospitals. Sales through deliverers rely on state owned or publicly traded companies that aggregate product offerings and handle logistics while the company remains responsible for after sales service. Sales through distributors involve small and medium sized businesses that market and sell the products to hospitals and then place orders with the company. In 2023 revenue from direct sales was approximately one point three million US dollars from deliverers fifteen point two million US dollars and from distributors fifteen point zero million US dollars. In 2024 the figures were three point one million US dollars from deliverers sixteen point eight million US dollars and from distributors seventeen point two million US dollars. In 2025 the figures were one point four million US dollars from deliverers two point seven million US dollars and from distributors eighteen point four million US dollars. Pricing varies by channel with distributors generally receiving lower prices than direct sales or sales through deliverers. The company does not rely on any single source supplier for its distribution segment and the distribution activity has little impact on overall revenue levels.

Baird Medical Investment Holdings Ltd holds a strong position within the Chinese microwave ablation medical device industry. According to the Frost & Sullivan Report for 2022 the top four manufacturers accounted for approximately eighty eight point four percent of sector sales. The company ranked third among these four with a market share of nineteen point zero percent in terms of sales revenue. It was ranked first in the niche of thyroid nodule and breast lump treatment based on both sales revenue and needle volume. Main competitors are ECO Medical Vison Medical and Canyon Medical. ECO Medical and Canyon Medical hold Class III registration certificates for microwave ablation devices used in liver cancer and thyroid nodule treatment while Vison Medical holds a Class III certificate for liver cancer only. Baird Medical Investment Holdings Ltd was the first company to obtain a Class III registration for a microwave ablation device specifically approved for thyroid nodule treatment in China. This first mover status provides a differentiator that is difficult for rivals to replicate. The company’s competitive advantages include its integrated approach that combines hardware innovation software intelligence and a comprehensive system mindset. It maintains an active research and development pipeline that explores AI integrated robotic systems for future product offerings. As of December 31 2025 the company held fifty four granted patents in the PRC and had eighteen pending patent applications. It also possessed four Class III registration certificates for its microwave ablation therapeutic instrument and accessories and three disposable microwave ablation needle variants with validity dates ranging from February 2028 to December 2028. The firm’s research and development team consisted of thirty members led by the chief technical officer Mr Rongjian Lu and incurred expenses of US$4 point three million in 2023 US$6 point two million in 2024 and US$20 point one million in 2025. Production capacity is supported by two leased manufacturing plants in Nanjing and Taicang with a combined floor area of approximately six thousand five hundred two square meters. The company employs a total of one hundred forty six staff across functions including production quality control sales and marketing research and development finance procurement and administration. These factors collectively reinforce Baird Medical Investment Holdings Ltd’s standing as a leading specialized provider of thyroid focused microwave ablation solutions in the PRC.

The company’s customer base consists principally of hospitals located throughout the Peoples Republic of China. Its products are used in Grade II and Grade III hospitals as defined by the Pilot Draft of the Hospital Hierarchy Management Scheme of the PRC. In 2023 approximately five zero five hospitals purchased its products of which about three one zero were Grade III facilities. In 2024 the number of hospitals increased to approximately five seven nine with Grade III hospitals remaining at about three one zero. In 2025 the hospital count rose to approximately six one four and the number of Grade III hospitals reached approximately three two nine. These hospitals are spread across twenty four provinces municipalities and autonomous regions indicating a broad national footprint. The company sells to hospitals through direct sales through deliverers and through third party distributors. Under the direct sales model the company engages directly with hospitals and retains responsibility for after sales service. Under the deliverer model the company works with state owned or publicly traded entities that aggregate product lines and manage logistics while the company provides after sales support. Under the distributor model the company treats the distributor as the customer and relies on the distributor’s own sales force to reach hospitals. The two largest customers in 2025 each accounted for twenty three point three percent and twelve point zero percent of total revenue respectively. In 2024 the four largest customers accounted for twenty five point six percent fourteen point four percent eleven point six percent and ten point two percent of revenue. In 2023 the two largest customers accounted for fourteen point three percent and ten point four percent of revenue. No single customer exceeded ten percent of revenue in 2023 while the concentration increased in later years due to the growth of the core microwave ablation business. The material terms of the agreements with these customers include standard sale of goods provisions such as product name model price and settlement of payment. The company does not disclose the specific names of its major customers in the filing.